Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study — Masatoshi Kudo (2021) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study
Shared by
Masatoshi Kudo
Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study
Article
2021
en
Authors
+12 more
Masatoshi Kudo
KT
Kaoru Tsuchiya
NK
Naoya Kato
Abstract
1 min read
Cabozantinib 60 mg/day has a favorable benefit/risk profile for Japanese patients with advanced HCC who have previously received one or two lines of systemic anticancer therapy including sorafenib. (Clinical trial registration: NCT03586973).
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2023
Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: Final results of a multicenter phase II study
Naoya Kato
,
Masatoshi Kudo
,
Kaoru Tsuchiya
,
Atsushi Hagihara
,
Kazushi Numata
,
Hiroshi Aikata
,
Yoshitaka Inaba
,
Shunsuke Kondo
,
Kenta Motomura
,
Naohiro Okano
,
Masafumi Ikeda
,
Manabu Morimoto
,
Shingo Kuroda
,
Akiko Kimura
Article
2021
Cabozantinib: An evolving therapy for hepatocellular carcinoma
Anthony B. El-Khoueiry
,
Diana L. Hanna
,
Josep M. Llovet
,
Robin Kate Kelley
Cancer Treatment Reviews
Article
2019
Sorafenib versus hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma: A Japanese multi-center large cohort study.
Sadahisa Ogasawara
,
Kazuomi Ueshima
,
Masafumi Ikeda
,
Yutaka Yasui
,
Takeshi Terashima
,
Tatsuya Yamashita
,
Shuntaro Obi
,
Shinpei Sato
,
Hiroshi Aikata
,
Takumi Ohmura
,
Hidekatsu Kuroda
,
Takamasa Ohki
,
Kengo Nagashima
,
Masayuki Kurosaki
,
Kazuaki Chayama
,
Shuichi Kaneko
,
Namiki Izumi
,
Naoya Kato
,
Masatoshi Kudo
,
Masao Omata
Article
2016
Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
Kenji Ikeda
,
Masatoshi Kudo
,
Seiji Kawazoe
,
Yukio Osaki
,
Masafumi Ikeda
,
Takuji Okusaka
,
Toshiyuki Tamai
,
Takuya Suzuki
,
Takashi Hisai
,
Seiichi Hayato
,
Kiwamu Okita
,
Hiromitsu Kumada
Article
2018
Predictor factor of survival in advanced hepatocellular carcinoma treated with sorafenib ∼a multicenter study∼
Chikara Ogawa
,
Masahiro Morita
,
Akina Omura
,
Mitsushige Shibatoge
,
Akemi Tsutsui
,
Tomonori Senoh
,
Takuya Nagano
,
Kouichi Takaguchi
,
Joji Tani
,
Asahiro Morishita
,
Hirohito Yoneyama
,
Tsutomu Masaki
,
Akio Moriya
,
Masaharu Ando
,
Akihiro Deguchi
,
Masatoshi Kudo
Discussion(0)
No comments yet. Be the first to comment.